Hyperglycemia Associated with Non-oral and Locally Injected Corticosteroids
|
|
- Myrtle Parks
- 6 years ago
- Views:
Transcription
1 PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2011 Hyperglycemia Associated with Non-oral and Locally Injected Corticosteroids Introduction Corticosteroids are used for a wide array of indications and are given by many different routes (oral, topical, intra-articular, inhaled, epidural, etc). Hyperglycemia is a well known complication of systemic (oral, intramuscular, intravenous) corticosteroid therapy, but less well recognized with other routes of administration. This document reviews hyperglycemia associated with corticosteroids given by topical, intraarticular, inhaled, and epidural routes of administration. Hyperglycemia and Corticosteroids Hyperglycemia is a well-known adverse effect of corticosteroid therapy. Orally administered corticosteroids have been shown to worsen glucose control in patients who already have diabetes and to cause hyperglycemia in patients without preexisting diabetes. 1 The incidence of corticosteroid-induced hyperglycemia is difficult to quantify because it is dependent on many patient-specific (type of diabetes, body mass index, age, family history) and treatment-specific (drug, dose, route of administration, duration) factors. 1 There are a number of mechanisms by which hyperglycemia occurs. Corticosteroids reduce glucose utilization, increase glucose production, inhibit the effects of insulin on myocytes and adipocytes, and increase hepatic glucose release. 2 The effects can be seen as early as 12 hours after beginning therapy. 3 In patients taking oral prednisone, the most pronounced hyperglycemic effect occurs one to two hours after a meal. 3 Certain corticosteroids have a more pronounced effect on blood glucose than others. For example, the synthetic corticosteroids prednisone and dexamethasone are four and 30 times more potent, respectively, than natural corticosteroids such as hydrocortisone at reducing carbohydrate metabolism. 3 There appears to be an association between the cumulative oral corticosteroid dose and the development of diabetes. In a case-control study, the risk of developing hyperglycemia requiring treatment was 1.77 (compared with controls) for patients receiving 1 mg to 10 mg a day of prednisone or the equivalent, 3.02 for 10 mg to 20 mg of daily prednisone, 5.82 for those taking 20 mg to 30 mg daily, and for those who received more than 30 mg of prednisone a day. 4 Similar results were seen by Ariza-Andraca and colleagues who found that the cumulative prednisone dose was significantly higher in those who developed diabetes compared with those who did not (26.6 g +/- 28 g vs 11.6 g +/- 11 g, p<0.02, odds ratio, 6.35). 5 In two other studies of patients without a history of diabetes with neurologic disease and those with respiratory disease, older age was also identified as a risk factor. 6,7 Of note, in the study of patients with respiratory disease, corticosteroid-induced diabetes occurred after a median of 193 days of therapy. 6 Upon discontinuation of the corticosteroid, the hyperglycemic effects of corticosteroids typically dissipate and blood glucose concentrations return to normal. 3 Intra-articular Corticosteroids Intra-articular injection of corticosteroids into a painful joint is common. Commonly injected joints include knee, shoulder, wrist, temporomandibular joint, ankle, and elbow. Intra-articular administration is touted as being effective while minimizing the systemic adverse effects commonly seen with systemic corticosteroid therapy. Despite widespread use, data regarding the effects on glucose are sparse and contradictory. 8 One of the first reports involved an elderly patient who developed a blood glucose concentration of greater than 1000 mg/dl
2 (55.6 mmol/l) within two hours after injection into the knee. 9 Since then, there have been a variety of conflicting reports regarding the effects of intraarticular injection on blood glucose. In a study of 18 patients with diabetes, no clinically significant effect was noted on blood glucose following 35 mg of methylprednisolone at the shoulder joint. 10 Conversely, two studies of corticosteroid injections in the knee showed increases in blood glucose. Following methylprednisolone 50 mg in nine patients with well-controlled diabetes, peak blood glucoses levels of approximately 300 mg/dl (16.7 mmol/l) were noted between five and 84 hours after injection and typically remained elevated for two to three days (but as long as five days). 11 However, one patient experienced a peak blood glucose level of 500 mg/dl (27.8 mmol/l) 48 hours after injection. 11 Following injection of 1 ml of Celestone Chronodose (a betamethasone depot product composed of 3 mg of betamethasone acetate and 3 mg of betamethasone sodium phosphate), six patients experienced significant preprandial and postprandial elevations of blood glucose for 18 to 46 hours after injection. 12 Increases in blood glucose were noted in patients with diabetes who received 10 mg methylprednisolone injections for trigger finger for five days. 13 In general, hyperglycemia following intraarticular injections of corticosteroids can be seen two to five days after injection [Evidence level B; nonrandomized study] ,14 In most patients, the clinical significance is minimal. However, in brittle patients with type 1 diabetes or in poorly controlled patients with type 2 diabetes, more frequent monitoring of blood glucose concentrations and diabetes medication dosage adjustments may be warranted. 14 Topical Corticosteroids Systemic effects of topical corticosteroids (applied to the skin) are determined by the bioavailability after topical administration. Topical corticosteroids such as mometasone furoate and fluticasone propionate have a small bioavailability with less than 1% systemically absorbed. Conversely, betamethasone dipropionate has a bioavailability of approximately of 44%. 3 (PL Detail-Document #271011: Page 2 of 5) In a nested case-control retrospective study of a drug database in the Netherlands, the association of topical corticosteroid use and diabetes was investigated. Corticosteroid use was defined as filling two or more prescriptions for topical corticosteroids and the onset of diabetes was defined as the first occurrence of filling a prescription for a diabetes medication. Control subjects were patients who filled two or more prescriptions for topical corticosteroids who did not subsequently fill a prescription for a diabetes medication. 15 The authors found that of the 192,893 topical corticosteroid users, 2212 developed diabetes. Current use of topical corticosteroids was associated with a 1.24-fold increased risk of diabetes (odds ratio 1.24, 95% confidence interval 1.11 to 1.40). When topical corticosteroids were used for more than 180 days, there was a fold risk in the development of diabetes (odds ratio 1.32, 95% confidence interval 1.14 to 1.54). Cumulative topical dose also appeared to be associated with the development of diabetes. 15 Based on the literature, it appears that topical corticosteroids can cause hyperglycemia [Evidence level B; case-control study]. 15 In patients using topical corticosteroids, especially for prolonged periods of time, or at a high steroid load (a combination of dose and potency), monitoring of blood glucose concentrations may be warranted. This is especially true for patients with an increased risk of absorption through the skin such as those with excoriated skin (psoriasis) or those who use topical steroids over large areas. Inhaled Corticosteroids Despite the widespread use of inhaled corticosteroids in the treatment of asthma and chronic obstructive pulmonary disease, there is limited information concerning their effects on blood sugar. One of the earliest reports of loss of glycemic control in a patient with diabetes receiving inhaled corticosteroids was reported in In this report, a 67-year old patient with well-controlled type 2 diabetes and asthma was started on fluticasone 2000 mcg daily. Although asthma symptoms improved, A1C increased from a baseline of 7 to 7.3% to 8.2%. After a fluticasone dose reduction to 1000 mcg daily, the A1C declined to 7.8%. In addition, glycosuria occurred when the patient was taking 2000 mcg daily, but
3 resolved when the dose was reduced to 500 mcg daily. 16 In a retrospective, population-based cohort trial patients who received three or more prescriptions for respiratory medications over a one-year period were studied. Only those without a diagnosis of diabetes and who had not received treatment for diabetes were included, so only patients with new-onset diabetes would be identified. Of 388,584 patients, 30,167 were identified as having new-onset diabetes during the 5.5 year follow-up period. Current use of inhaled corticosteroids was associated with a 1.34-fold increased in diabetes (odds ratio 1.34, 95% confidence interval 1.29 to 1.39). The greatest increase in risk occurred in those treated with the highest doses of inhaled corticosteroids (equivalent to fluticasone 1000 mcg daily or more, relative risk 1.64, 95% confidence interval 1.52 to 1.76). 17 The first small prospective randomized, double-blind, placebo-controlled study to evaluate the effects of inhaled corticosteroids in patients with type 2 diabetes was reported in In this study, 12 patients were randomized to either fluticasone 440 mcg twice daily and oral placebo or placebo inhaler and oral montelukast. After six weeks, patients were switched to the opposite treatment. A1C concentrations were measured during each phase of therapy. 18 Of the ten patients who completed the study, the changes in A1C were small but statistically significant. The mean change in A1C was 0.11% compared with baseline when using fluticasone. Conversely, during the montelukast phase, the A1C change from baseline was -0.14%. During inhaled fluticasone phase, seven patients had an increase in A1C over baseline, one was unchanged, and two had a reduction. During the montelukast phase, six patients experienced a reduction in A1C compared with baseline, two had an increase, and one remained unchanged. 18 Although there are no trials of intranasal corticosteroids and their effect on glucose concentrations, it is likely that this route of administration can also lead to hyperglycemia. Based on limited information, it appears to be prudent to monitor blood sugar values in patients using inhaled corticosteroids, especially in those receiving higher doses (e.g., fluticasone 1000 mcg/day or higher or the equivalent) (PL Detail-Document #271011: Page 3 of 5) [Evidence level B; lower quality RCT and case control studies]. 17,18 In patients who develop hyperglycemia, consider lowering the inhaled steroid dose and adding other therapies such as montelukast (Singulair), tiotropium (Spiriva), or a long-acting beta-agonist (Serevent, etc), depending on the condition being treated. Epidural Corticosteroids As with other non-oral routes of administration, epidural corticosteroids can increase glucose concentrations. Glucose elevations can persist for up to two weeks after an epidural injection. 20 In a report of 18 patients (four with diabetes and 14 without diabetes) who received epidural injections, investigators found that epidural injections caused increased postprandial glucose concentrations in all patients. They also noted that these increases were more pronounced and lasted longer in patients with diabetes compared to those without diabetes. 21 However, the statistical analysis of the data included data from an additional 11 patients who received intraarticular injections into the shoulder. Therefore, it is impossible to tease out those who received only epidural corticosteroids. 21 Based on this study, it appears that epidural injections can cause hyperglycemia and that blood glucose monitoring for up to two weeks may be warranted in patients, especially in those with preexisting diabetes [Evidence level B; nonrandomized study]. 21 Conclusion There is no consensus on the optimal monitoring and treatment of corticosteroidinduced hyperglycemia. In general, for most patients with normal pancreatic function and no insulin resistance, inhaled or topical corticosteroids are not likely to cause significant hyperglycemia. Additionally, in patients in whom corticosteroid therapy is for a limited time (e.g., a single intra-articular injection), no treatment may be necessary. 19 In patients with risk factors for diabetes such as metabolic syndrome or a history of impaired fasting glucoses, or in those with pre-existing diabetes, monitoring of blood glucose is warranted. The optimal timing and frequency of glucose monitoring is unknown.
4 Hyperglycemia has been reported with topical, intra-articular, inhaled, and epidural corticosteroids. Topical steroids can cause hyperglycemia with high doses or prolonged use, especially in at-risk patients with diffuse skin conditions such as psoriasis. Patients using higher dose or potency topical steroids for longer than six months should be monitored. Inhaled steroids can increase the risk of hyperglycemia when used in high doses, such as fluticasone 1000 mcg/day or more. Patients, especially those with diabetes or at risk for diabetes, should be monitored. Steroid injections into joints can cause hyperglycemia for about two to five days in patients, and potentially longer for long-acting, depot corticosteroid formulations. Finally, epidural injections of corticosteroids can increase blood glucose concentrations for up to two weeks after injection, and this effect appears more pronounced in patients with pre-existing diabetes. If significant hyperglycemia occurs, a trial of a lower steroid dose or non-steroid treatment should be considered, if possible. Optimal treatment for corticosteroid-induced hyperglycemia in patients who require long-term corticosteroids is not known. It appears rational for a patient who has not had hyperglycemia in the past to modify their diet and exercise to lower blood glucose. In patients taking oral antidiabetes medications, increasing the dose of these agents can be tried. Finally, in patients already taking insulin, increasing the dose of insulin appears logical. Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication. Project Leader in preparation of this PL Detail- Document: Neeta Bahal O Mara, Pharm.D., BCPS, Drug Information Consultant References 1. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15: Keenan GF. Management of complications of glucocorticoid therapy. Clin Chest Med 1997;18: Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010;43: (PL Detail-Document #271011: Page 4 of 5) 4. Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994;154: Ariza-Andraca RC, Barile-Fabris LA, Frati-Munari AC, Baltazar-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998;29: Kim SY, Yoo CG, Lee CT, et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci 2011;26: Iwamoto T, Kagawa W, Naito Y, et al. Steroidinduced diabetes and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004;24: Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009;28: Black DM, Filak AT. Hyperglycemia with noninsulin-dependent diabetes following intraarticular steroid injection. J Fam Pract 1989;28: Habib GS, Abu-Ahmad R. Lack of effect of corticosteroid injections at the shoulder joint on blood glucose levels in diabetic patients. Clin Rheumatol 2007;26: Habib GS, Bashir M, Jabbour A. Increased blood glucose levels following intra-articular injection of methylprednisolone acetate in patients with controlled diabetes and symptomatic osteoarthritis of the knee. Ann Rheum Dis 2008;67: Habib G, Safia A. The effect of intra-articular injection of betamethasone acetate/betamethasone sodium phosphate on blood glucose levels in controlled diabetic patients with symptomatic osteoarthritis of the knee. Clin Rheumatol 2009;28: Wang AA, Hutchinson DT. The effect of corticosteroid injection for trigger finger on blood glucose level in diabetic patients. J Hand Surg Am 2006;31: MacMahon PJ, Eustace SJ, Kavanagh EC. Injectable corticosteroid and local anesthetic preparations: a review for radiologists. Radiology 2009;252: Van der Linden MW, Penning-van Beest FJ, Nijsten T, Herings RM. Topical corticosteroids and the risk of diabetes mellitus. A nested case-control study in the Netherlands. Drug Saf 2009;32: Faul JL, Tormey W, Tormey V, Burke C. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ 1998;317: Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risk of diabetes onset and progression. Am J Med 2010;123: Faul JL, Wilson SR, Chu JW, et al. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res 2009;7: Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults. Frequency, screening and prevention. Drug Saf 2007;30:
5 (PL Detail-Document #271011: Page 5 of 5) 20. Spaccarelli KC. Lumbar and caudal epidural corticosteroid injections. Mayo Clin Proc 1996;71: Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and non-diabetic patients. Joint Bone Spine 2007;74: Levels of Evidence In accordance with the trend towards Evidence-Based Medicine, we are citing the LEVEL OF EVIDENCE for the statements we publish. Level Definition A High-quality randomized controlled trial (RCT) High-quality meta-analysis (quantitative systematic review) B Nonrandomized clinical trial Nonquantitative systematic review Lower quality RCT Clinical cohort study Case-control study Historical control Epidemiologic study C Consensus Expert opinion D Anecdotal evidence In vitro or animal study Adapted from Siwek J, et al. How to write an evidence-based clinical review article. Am Fam Physician 2002;65: Cite this document as follows: PL Detail-Document, Hyperglycemia Associated with Non-oral and Locally Injected Corticosteroids. Pharmacist s Letter/Prescriber s Letter. October Evidence and Recommendations You Can Trust 3120 West March Lane, P.O. Box 8190, Stockton, CA ~ TEL (209) ~ FAX (209) Subscribers to the Letter can get PL Detail-Documents, like this one, on any topic covered in any issue by going to or
Sepsis and Septic Shock: New Definitions for Adults
PL Detail-Document #320424 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2016 Sepsis and Septic
More informationMusculoskeletal corticosteroid use:
Musculoskeletal corticosteroid use: Types, Indications, Contraindications, Equivalent doses, Frequency of use and Adverse effects. Dr Jide Olubaniyi MBBS, FRCR Dr Sean Crowther MB BCh, MRCS, FRCR Dr Sukhvinder
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationAspirin for the Prevention of Cardiovascular Disease
Detail-Document #250601 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2009 ~ Volume 25 ~ Number 250601 Aspirin for the Prevention of Cardiovascular
More informationEffect of Local Corticosteroid Injection of the Hand and Wrist on Blood Glucose in Patients With Diabetes Mellitus
Effect of Local Corticosteroid Injection of the Hand and Wrist on Blood Glucose in Patients With Diabetes Mellitus Louis W. Catalano III, MD; Steven Z. Glickel, MD; O. Alton Barron, MD; Richard Harrison,
More informationSteroid Hyperglycemia Chris Lewis, ARNP, BC-ADM, CDE
Steroid Hyperglycemia Chris Lewis, ARNP, BC-ADM, CDE Objectives Explain the pathophysiology of steroid induced hyperglycemia Understand different glucocorticoid duration of action and how that may affect
More informationType 2 Diabetes Mellitus in Patients with a Prior History of Corticosteroid-induced Hyperglycemia
original research Type 2 Diabetes Mellitus in Patients with a Prior History of Corticosteroid-induced Hyperglycemia Jennifer Levine DeZubay, PharmD; Richard H. Drew, PharmD, MS, FCCP, FIDP; Jennifer Smith,
More informationHTN: 80 mg once daily 23,f 80 mg once daily 23,f Hypertension 40, 80 mg $82.66 (80 mg once daily) HTN: 8-32 mg daily in one or two divided doses 1
Detail-Document #260301 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2010 ~ Volume 26 ~ Number 260301 Comparison of Angiotensin Receptor
More informationCompounding KI for Radiation Exposure
PL Detail-Document #270323 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2011 Compounding KI for
More informationInterventions to improve adherence to inhaled steroids for asthma. Respiratory department
Interventions to improve adherence to inhaled steroids for asthma Respiratory department Content Overview Research References Overview Asthma is a chronic breathing condition that affects more than 300
More informationASTHMA TREATMENT AND THE HPA AXIS
ASTHMA TREATMENT AND THE HPA AXIS Paul A. Greenberger, M.D. 7/12/2010 10:30-10:50 10:50 Objectives To review HPA axis suppression and its clinical significance in adults and children To describe methods
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationCardiovascular Risk in Patients with Diabetes
PL Detail-Document #270516 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2011 Cardiovascular Risk
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationAustralian Asthma Handbook. Key table and figures Version 1.2
Australian Asthma Handbook Key table and figures Version 1.2 DIAGNOSIS OF ASTHMA Figure. Steps in the diagnosis of asthma in adults Table. Findings that increase or decrease the probability of asthma in
More informationImportant facts about ORTHOVISC mini
ORTHOVISC mini A targeted treatment for small joint pain. An increasing number of patients suffer from osteoarthritis (OA), the multisymptomatic joint disease characterized by cartilage degeneration and
More informationCLINICAL GUIDELINES. Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P.
CLINICAL GUIDELINES Summary of Literature and Recommendations Concerning Immunization and Steroid Injections Thomas J. Gilbert M.D., M.P.P. 11/2/15 Several practices routinely delay steroid injections
More informationINHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement.
INHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement. Samy Suissa, PhD, Marc Baltzan, MD, MSc, Richard Kremer, MD, Pierre Ernst, MD, MSc 26 METHODS Source of data We used
More informationConversion of iv hydrocortisone to oral
Search Search Conversion of iv hydrocortisone to oral Converting systemic corticosteroids. A patient is being treated with methylprednisolone 20 mg IV q6 hours for some. Oral absorption of hydrocortisone,.
More informationBudesonide prednisone equivalent
Budesonide prednisone equivalent Search 23-4-2013 Equivalence between oral prednisone. Home Ask The Expert Equivalence between oral prednisone and. 1000 mcg/day of budesonide was equivalent to. Up to 20%
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationBritish Journal of Rheumatology 1991; 30:
British Journal of Rheumatology 1991; 30:468-470 CASE REPORT CARPAL TUNNEL SYNDROME COMPLICATED BY REFLEX SYMPATHETIC DYSTROPHY SYNDROME BY M.-A. FITZCHARLES AND J.M. ESDAILE Rheumatic Disease Unit, McGill
More informationCataracts are a major public health problem,
Eur Respir J 2006; 27: 1168 1174 DOI: 10.1183/09031936.06.00043005 CopyrightßERS Journals Ltd 2006 Low-dose inhaled and nasal corticosteroid use and the risk of cataracts P. Ernst*,#, M. Baltzan*,",+,
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationTRANSPARENCY COMMITTEE. Opinion. 29 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 29 November 2006 HEXATRIONE 2% suspension for injection (intra-articular) Box containing one 2-ml vial - CIP code:
More informationResearch in Real Life
Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationCommon Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
More informationThis is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis.
This is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/98736/ Version: Accepted Version
More informationDrug Utilization Evaluation of Corticosteroids Based on Safety: A Prospective Observational Study.
Drug Utilization Evaluation of Corticosteroids Based on Safety: A Prospective Observational Study. 1 c. Dhandapani, 2 K.S.G. Arulkumaran, 3 P. Asha* KMCH College of Pharmacy COIMBATORE, Tamil Nadu, India
More informationTREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN. Dr Lại Lê Hưng Respiratory Department
TREAMENT OF RECURRENT VIRUS-INDUCED WHEEZING IN YOUNG CHILDREN Dr Lại Lê Hưng Respiratory Department Literature review current through: Feb 2013. This topic last updated: Aug 14, 2012 INTRODUCTION Wheezing
More informationAamir Hussain MD Maya D. Srivastava MD Michael Moore MD
Assessment of Bone Health in patients with Eosinophilic Esophagitis Aamir Hussain MD Maya D. Srivastava MD Michael Moore MD Background Eosinophilic esophagitis is defined as a chronic, immune/antigen mediated,
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationORTHOPEDIC PRIMARY CARE Joint Injections in Primary Care. Jackson Orthopaedic Foundation
ORTHOPEDIC PRIMARY CARE Joint Injections in Primary Care Jackson Orthopaedic Foundation Joint Injections in Primary Care Kathleen A. Geier, DNP, NP, ONC A.J. Benham, DNP, NP, ONC kgeier@jacksonortho.org
More information5/15/2018 DISCLOSURE OBJECTIVES. FLORIDA HOSPITAL ORLANDO Not for profit organization Acute care medical center 1,368 licensed beds BACKGROUND
DISCLOSURE PHARMACIST DIRECTED MANAGEMENT OF GLUCOCORTICOID INDUCED HYPERGLYCEMIA AT A LARGE COMMUNITY HOSPITAL Jill Zaccardelli, PharmD PGY1 Pharmacy Resident Florida Hospital Orlando Jill.Zaccardelli@flhosp.org
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationQ: Should patients with mild asthma
1-MINUTE CONSULT CME CREDIT EDUCATIONAL OBJECTIVE: Readers will consider prescribing inhaled corticosteroids to their patients who have mild persistent asthma brief answers to specific clinical questions
More informationAsthma medications: Know your options - MayoClinic.com. Asthma medications: Know your options
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationAcute Migraine Treatment in Adults
PL Detail-Document #301104 This PL Detail-Document gives subscribers additional insight related the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER November 2014 Acute Migraine Treatment
More informationOverview of inhaled and nasal corticosteroids and haematoma
Overview of inhaled and nasal corticosteroids and haematoma Introduction Inhaled glucocorticoids (ICS) are widely used to treat asthma and chronic obstructive pulmonary disease (COPD). Nasal glucocorticoids
More information1.* Dosage/Administration
Pramlintide (Symlin ) [Developed, February 2006; Revised, May 2006; January 2010; December 2011; October 2013] MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE Information on indications for use or
More informationChronic Disease Management when Resources are Limited
Chronic Disease Management when Resources are Limited Paul R. Larson MD, MS, DIM&PH Director, Global Health Education UPMC St. Margaret Family Medicine Residency Pittsburgh, PA larsonpr@upmc.edu Disclosures
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationThe most recent estimates suggest that. A study of inpatient diabetes care on medical wards. Saqib Javed, Yaser Javed, Kate Barnabas, Kalpana Kaushal
A study of inpatient diabetes care on medical wards Saqib Javed, Yaser Javed, Kate Barnabas, Kalpana Kaushal Article points 1. It is well established that poor glycaemic control is associated with increased
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMetformin Hydrochloride
Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin
More informationSpecial Situations 1
Special Situations 1 Outline Continuous Nutrition Tube feeds TPN Steroids Pumps Perioperative BG Control 2 Patient receiving continuous TF or TPN Continuous nutrition coverage options: Analog q4hr Regular
More informationSection: Medicine Last Reviewed Date: June Policy No: 130 Effective Date: September 1, 2014
Medical Policy Manual Topic: Manipulation Under Anesthesia for the Treatment of Pain Date of Origin: April 2009 Section: Medicine Last Reviewed Date: June 2014 Policy No: 130 Effective Date: September
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationNOVOLIZER BUDESONIDE. Corticosteroids for the treatment of chronic asthma in children under the age of 12 years
NOVOLIZER BUDESONIDE Corticosteroids for the treatment of chronic asthma in children under the age of 12 years Response to the assessment report produced by the Peninsula Technology Assessment group and
More informationIatrogenic Cushing s Syndrome with Co-Administered Ritonavir and Corticosteroid via Inhaled, Intranasal, & Topical Route
Abstract #384 Category A1 Iatrogenic Cushing s Syndrome with Co-Administered Ritonavir and Corticosteroid via Inhaled, Intranasal, & Topical Route Rory Okasaki-Gutierrez, Pharm.D. Co-Investigators: Patricia
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationFURAMIST Nasal Spray (Fluticasone furoate )
Published on: 21 Jan 2016 FURAMIST Nasal Spray (Fluticasone furoate ) Composition Each spray contains: Fluticasone furoate 27.5 mcg Dosage Form Aqueous intranasal spray Pharmacology Pharmacodynamics Fluticasone
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationDrug Monograph. Brand Name: Arcapta Neohaler. Generic Name: Indacaterol. Manufacturer¹,²: Novartis
Drug Monograph Brand Name: Arcapta Neohaler Generic Name: Indacaterol Manufacturer¹,²: Novartis Drug Class¹,²,³, : Beta2-Adrenergic Agonist, Long-Acting Uses: Labeled Uses¹,²,³, : Used for long-term maintenance
More informationPublic Assessment Report Scientific discussion. Metoject Metojectpen (methotrexate disodium) SE/H/643/01/DC SE/H/643/02-11/DC
Public Assessment Report Scientific discussion Metoject Metojectpen (methotrexate disodium) SE/H/643/01/DC SE/H/643/02-11/DC This module reflects the scientific discussion for the approval of Metoject
More informationPhysical Activity/Exercise Prescription with Diabetes
Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More information2013 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients 18 and older)
2013 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients 18 and older) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy Gender:
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationCommon Cardiovascular Risk Calculators
PL Detail-Document #300102 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Common Cardiovascular
More information2014 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients aged 18 and older)
2014 Physician Quality Reporting System Data Collection Form: Inflammatory Bowel Disease (IBD) (for patients aged 18 and older) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationCharacteristics of Transdermal Patches
This Clinical Resource gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER July 2017 ~ Resource #330733 Characteristics of Transdermal
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationUS max daily dose i Food and Drug Administration [2]
APPENDIX 2 etable 1. Regulatory limits on total daily dose for asthma medications Drugs Canadian max daily dose i Health Canada [1] US max daily dose i Food and Drug Administration [2] European max daily
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationDIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL
DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL Facility: Date: Data Collector s name: Email/Phone: Purpose: To evaluate your facility practices regarding communication of requisite diabetes
More informationOriginal Article. Kishore Kumar K 1, Sai Samrat K 2, Sony Reddy S 3 INTRODUCTION
Original Article A Comparative Study between Intramuscular and Oral Methylprednisolone Acetate in the Treatment of Asthma Exacerbation Following Discharge from the Hospital Kishore Kumar K 1, Sai Samrat
More informationReducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital
Reducing COPD Exacerbation Readmissions in a Community-Based Teaching Hospital Dawn Waddell, PharmD, BCPS Clinical Pharmacy Manager Lisa Kingdon, PharmD, BCPS Clinical Pharmacy Specialist Dawn Waddell
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCorticosteroids. Abdulmoein Al-Agha, FRCPCH Professor of Pediatric Endocrinology, King Abdulaziz University Hospital,
Corticosteroids Abdulmoein Al-Agha, FRCPCH Professor of Pediatric Endocrinology, King Abdulaziz University Hospital, http://aagha.kau.edu.sa History 1855 Addison's disease 1856 Adrenal glands essential
More informationDisclosures. Glycemic Control in the Intensive Care Unit. Objectives. Hyperglycemia. Hyperglycemia. History. No disclosures
Disclosures Glycemic Control in the Intensive Care Unit No disclosures Jorie Frasiolas, Pharm.D., BCPS Clinical Pharmacy Manager, CTICU NewYork-Presbyterian Hospital Columbia University Medical Center
More informationDrug Class Monograph
Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Monograph Drugs: alogliptin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin), Jentadueto (linagliptin/metformin),
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationPreschool Wheeze. AC Jeevarathnum 04/03/16. Paediatric Pulmonologist Steve Biko Academic Hospital
Preschool Wheeze AC Jeevarathnum Paediatric Pulmonologist Steve Biko Academic Hospital MBBCh FcPaed(SA) MMED Dip Allergy(SA) Cert Pulm(Paed)(SA) European Respiratory Diploma 04/03/16 Overview Introduction
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for budesonide,
More informationSelf Monitoring of Blood Glucose (SMBG)
Self Monitoring of Blood Glucose (SMBG) DCPNS Provincial Workshop April 28, 2011 Presenter: Pam McLean-Veysey Team Leader, Drug Evaluation Unit, Capital Health 1 Disclosure Pam McLean-Veysey provides drug
More informationIn 2002, it was reported that 72 of 1000
REPORTS Aligning Patient Care and Asthma Treatment Guidelines Eric Cannon, PharmD Abstract This article describes how the National Asthma Education and Prevention Program Guidelines for the Diagnosis and
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSteroid intra-articular injections for foot and ankle conditions: How effective are they?
The Foot and Ankle Online Journal Official Publication of the International Foot & Ankle Foundation faoj.org / ISSN 1941-6806 Steroid intra-articular injections for foot and ankle conditions: How effective
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information